Companies
Institute for Protein Design
The global epicenter of de novo design, pioneering open-source architectures like RFdiffusion and ProteinMPNN.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| foundries-design | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Partnership | University of Washington (affiliated/housed within School of Medicine) | research.washington.edu |
| Research focus | de novo protein design, computational biomolecular design, vaccine and therapeutic development, self-assembling nanostructures, enzyme engineering, and artificial intelligence for protein modeling | research.washington.edu · ipd.uw.edu |
| Facility | Core R&D Labs, including labs for protein production, peptide synthesis, electron/light microscopy, X-ray crystallography, and process development | ipd.uw.edu |
| Grant | $33M annual research budget; $7M grant from Washington Research Foundation (2026) | firstwordpharma.com · ipd.uw.edu |
| Publications | 50+ scientific publications per year; 100+ patents issued | ipd.uw.edu |
| Principal staff | David Baker (Director) | research.washington.edu · ipd.uw.edu |
| Headcount | 250+ total members (as of 2023) | ipd.uw.edu |
Independent sources: firstwordpharma.com · ipd.uw.edu · research.washington.edu
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Generative protein design | foundries-design | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.